Atty. Dkt. No. 039386-1099 Application Serial No. 09/857,826

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

TANG et al.

Title:

NEURON-ASSOCIATED PROTEINS

Appl. No.:

09/857,826

Filing Date: 6/7/2001

Examiner:

Sharon L. Turner

Art Unit:

1647

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

10/27/2004 RFEKADU1 00000038 09857826

01 FC:1806

180.00 OP



TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date _10126104

FOLEY & LARDNER LLP

Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5143


Facsimile:

Telephone: (202) 945-6142

(202) 672-5399

Eve L. Frank

Attorney for Applicant Registration No. 46,785



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number. Substitute for form 1449B/PTO Complete if Known Application Number 09/857826 INFORMATION DISCLOSURE 6/7/2001 STATEMENT BY APPLICANT Date Submitted: October 26, 2004 001 2 ng Date Y. Tom Tang おまt Named Inventor 1647 oup Art Unit (use as many sheets as necessal Examiner Name Sharon L. Turner 2 Attorney Docket Number 039386-1099 1 of Sheet

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant		
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		

Examiner Cite Foreign Patent Document Name of Patentee or Cited Document Where Releval Passages or Relevant Passages or Relevant Passages or Relev				DREIGN PATENT DOCUMEN			
		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Cited Document		Kind Code⁵		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		XU et al., PMEPA1, an Androgen-regulated NEDD4-binding Protein, Exhibits Cell Growth Inhibitory Function and Decreased Expression during Prostate Cancer Progression, Cancer Research, August 1, 2003, pp. 4299-4304, No. 63	
		RAE et al., Characterization of a Novel Gene, STAG1/PMEPA1, Upregulated in Renal Cell Carcinoma and Other Solid Tumors, Molecular Carcinogenisis, 2001, pp. 44-53, No. 32	

-			, <u> </u>
Examiner Signature		Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.